Patient Selection for Sustaining Outcomes in the Pediatric Population with the t:slim X2 Insulin Pump with Control-IQ Technology
Add to:
On October 13th, scientists and clinicians who have been closely involved in the development and launch of Control-IQ™ technology for the t:slim X2™ insulin pump discussed patient selection and benefits in the pediatric population at the ISPAD 2021 Virtual Conference. Discussion included recent clinical data and patient-reported outcomes. Time was set aside at the end for a live question and answer session.
Patient Selection for Sustaining Outcomes in the Pediatric Population with the t:slim X2 Insulin Pump with Control-IQ Technology
* Tandem Diabetes Care will have an exhibit table at each event, but Tandem is not the event organizer and does not have control of the information shared outside of its exhibit space.
Leave a commentOrder by
Newest on top Oldest on top